Stock Detail
HUMAN GENOME SCIENCES INC
Biotechnology
HGSI @ Yahoo Finance | HGSI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $8.74 | $9.10 | $0.00 | 0.00% | 0.00 | $9.14 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $9.02 | $8.71 | 5.92M | 1.74B | 5.84M | 0.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 9.24 | 8.99 | 8.85 | 8.60 | 8.46 |
Stock Profile
Human Genome Sciences, Inc. operates as a biopharmaceutical company with a pipeline of novel protein and antibody drugs. The company's drugs in clinical development include LymphoStat-BTM for the treatment of lupus and rheumatoid arthritis; AlbuferonTM for the treatment of chronic hepatitis C; HGS-ETR1, HGS-ETR2, HGS-TR2J for the treatment of solid and hematopoietic cancers; CCR5 mAb for the treatment of HIV/ AIDS; and ABthraxTM for the treatment of anthrax infection. It has various strategic partners, including GlaxoSmithKline, Takeda, Schering-Plough, Sanofi-Synthelabo, Merck KGaA, Transgene, MedImmune, Inc., and Pharmacia & Upjohn. Human Genome Sciences was founded in 1992 and is headquartered in Rockville, Maryland.